There are some proteins that still evade scientists in the race for better therapeutics. Some of the most elusive drug targets in cancer research are RAS oncoproteins. In a paper published this July, researchers demonstrated the delivery of an extremely potent pan-RAS-cleaving enzyme, opening the door for the first targeted pan-RAS inhibitor for cancer therapy. In this episode we speak with two of the researchers from this project, a cancer biologist and a protein engineer, to learn what sparked their collaboration and what their system means for the future of cancer biologics.